Cargando…
Current therapies and novel approaches for biliary diseases
Chronic liver diseases that inevitably lead to hepatic fibrosis, cirrhosis and/or hepatocellular carcinoma have become a major cause of illness and death worldwide. Among them, cholangiopathies or cholestatic liver diseases comprise a large group of conditions in which injury is primarily focused on...
Autores principales: | Rajapaksha, Indu G, Angus, Peter W, Herath, Chandana B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318481/ https://www.ncbi.nlm.nih.gov/pubmed/30622832 http://dx.doi.org/10.4291/wjgp.v10.i1.1 |
Ejemplares similares
-
The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice
por: Rajapaksha, Indu G., et al.
Publicado: (2018) -
Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options
por: Rajapaksha, Indu G., et al.
Publicado: (2021) -
Liver‐Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug‐Resistant Gene 2‐Knockout Mice
por: Rajapaksha, Indu G., et al.
Publicado: (2019) -
Cirrhotic portal hypertension: From pathophysiology to novel therapeutics
por: Gunarathne, Lakmie S, et al.
Publicado: (2020) -
Mas‐related G protein‐coupled receptor type D antagonism improves portal hypertension in cirrhotic rats
por: Gunarathne, Lakmie S., et al.
Publicado: (2022)